Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas

Hatim Husain, William Savage, Stuart A Grossman, Xiaobu Ye, Peter C. Burger, Allen D Everett, Chetan Bettegowda, Luis A. Diaz, Cherie Blair, Katharine E. Romans, Matthias Holdhoff

Research output: Contribution to journalArticle

Abstract

Therapies that disrupt or repair blood-brain barrier integrity can result in major changes in MRI images even when the tumor volume remains constant. Thus, a reliable blood-based tumor biomarker could significantly improve clinical care and research studies in these patients. This study was performed to assess plasma concentrations of glial fibrillary acidic protein (GFAP) in patients with high- and low-grade gliomas before and after debulking surgery. Pre-operative plasma was collected from 33 patients with radiation- and chemotherapy-naïve gliomas. Additional plasma was collected 24-48 h post-operatively from 23 of these patients. Plasma GFAP (pGFAP) concentrations were determined using an electrochemiluminescent immunoassay and were analyzed as a function of tumor grade, tumor GFAP expression, the integrity of the blood-brain barrier, and post-operative status. Detectable pGFAP levels (≥0.04 ng/mL) were found pre-operatively in 52 % of patients and post-operatively in 96 %. Detectable pGFAP was more common in patients with WHO grade IV (100 %) than WHO grade III (56 %) or WHO grade II gliomas (20 %). No patient with undetectable GFAP had WHO grade IV glioma. Higher pGFAP concentrations were also associated with contrast enhancement but not related to tumor GFAP expression. GFAP is commonly detected in the plasma of patients with high-grade gliomas. pGFAP levels rise rather than fall following debulking surgery which is probably a result of surgical trauma. GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes.

Original languageEnglish (US)
Pages (from-to)123-127
Number of pages5
JournalJournal of Neuro-Oncology
Volume109
Issue number1
DOIs
StatePublished - Aug 2012

Fingerprint

Glial Fibrillary Acidic Protein
Glioma
Blood Proteins
Blood-Brain Barrier
Neoplasms
Tumor Biomarkers
Tumor Burden
Immunoassay
Longitudinal Studies
Biomarkers
Radiation
Drug Therapy

Keywords

  • Biomarker
  • Circulating tumor marker
  • Glial fibrillary acidic protein
  • Glioblastoma
  • Glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. / Husain, Hatim; Savage, William; Grossman, Stuart A; Ye, Xiaobu; Burger, Peter C.; Everett, Allen D; Bettegowda, Chetan; Diaz, Luis A.; Blair, Cherie; Romans, Katharine E.; Holdhoff, Matthias.

In: Journal of Neuro-Oncology, Vol. 109, No. 1, 08.2012, p. 123-127.

Research output: Contribution to journalArticle

@article{2096275c41894a12930d7e8a1028beb9,
title = "Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas",
abstract = "Therapies that disrupt or repair blood-brain barrier integrity can result in major changes in MRI images even when the tumor volume remains constant. Thus, a reliable blood-based tumor biomarker could significantly improve clinical care and research studies in these patients. This study was performed to assess plasma concentrations of glial fibrillary acidic protein (GFAP) in patients with high- and low-grade gliomas before and after debulking surgery. Pre-operative plasma was collected from 33 patients with radiation- and chemotherapy-na{\"i}ve gliomas. Additional plasma was collected 24-48 h post-operatively from 23 of these patients. Plasma GFAP (pGFAP) concentrations were determined using an electrochemiluminescent immunoassay and were analyzed as a function of tumor grade, tumor GFAP expression, the integrity of the blood-brain barrier, and post-operative status. Detectable pGFAP levels (≥0.04 ng/mL) were found pre-operatively in 52 {\%} of patients and post-operatively in 96 {\%}. Detectable pGFAP was more common in patients with WHO grade IV (100 {\%}) than WHO grade III (56 {\%}) or WHO grade II gliomas (20 {\%}). No patient with undetectable GFAP had WHO grade IV glioma. Higher pGFAP concentrations were also associated with contrast enhancement but not related to tumor GFAP expression. GFAP is commonly detected in the plasma of patients with high-grade gliomas. pGFAP levels rise rather than fall following debulking surgery which is probably a result of surgical trauma. GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes.",
keywords = "Biomarker, Circulating tumor marker, Glial fibrillary acidic protein, Glioblastoma, Glioma",
author = "Hatim Husain and William Savage and Grossman, {Stuart A} and Xiaobu Ye and Burger, {Peter C.} and Everett, {Allen D} and Chetan Bettegowda and Diaz, {Luis A.} and Cherie Blair and Romans, {Katharine E.} and Matthias Holdhoff",
year = "2012",
month = "8",
doi = "10.1007/s11060-012-0874-8",
language = "English (US)",
volume = "109",
pages = "123--127",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas

AU - Husain, Hatim

AU - Savage, William

AU - Grossman, Stuart A

AU - Ye, Xiaobu

AU - Burger, Peter C.

AU - Everett, Allen D

AU - Bettegowda, Chetan

AU - Diaz, Luis A.

AU - Blair, Cherie

AU - Romans, Katharine E.

AU - Holdhoff, Matthias

PY - 2012/8

Y1 - 2012/8

N2 - Therapies that disrupt or repair blood-brain barrier integrity can result in major changes in MRI images even when the tumor volume remains constant. Thus, a reliable blood-based tumor biomarker could significantly improve clinical care and research studies in these patients. This study was performed to assess plasma concentrations of glial fibrillary acidic protein (GFAP) in patients with high- and low-grade gliomas before and after debulking surgery. Pre-operative plasma was collected from 33 patients with radiation- and chemotherapy-naïve gliomas. Additional plasma was collected 24-48 h post-operatively from 23 of these patients. Plasma GFAP (pGFAP) concentrations were determined using an electrochemiluminescent immunoassay and were analyzed as a function of tumor grade, tumor GFAP expression, the integrity of the blood-brain barrier, and post-operative status. Detectable pGFAP levels (≥0.04 ng/mL) were found pre-operatively in 52 % of patients and post-operatively in 96 %. Detectable pGFAP was more common in patients with WHO grade IV (100 %) than WHO grade III (56 %) or WHO grade II gliomas (20 %). No patient with undetectable GFAP had WHO grade IV glioma. Higher pGFAP concentrations were also associated with contrast enhancement but not related to tumor GFAP expression. GFAP is commonly detected in the plasma of patients with high-grade gliomas. pGFAP levels rise rather than fall following debulking surgery which is probably a result of surgical trauma. GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes.

AB - Therapies that disrupt or repair blood-brain barrier integrity can result in major changes in MRI images even when the tumor volume remains constant. Thus, a reliable blood-based tumor biomarker could significantly improve clinical care and research studies in these patients. This study was performed to assess plasma concentrations of glial fibrillary acidic protein (GFAP) in patients with high- and low-grade gliomas before and after debulking surgery. Pre-operative plasma was collected from 33 patients with radiation- and chemotherapy-naïve gliomas. Additional plasma was collected 24-48 h post-operatively from 23 of these patients. Plasma GFAP (pGFAP) concentrations were determined using an electrochemiluminescent immunoassay and were analyzed as a function of tumor grade, tumor GFAP expression, the integrity of the blood-brain barrier, and post-operative status. Detectable pGFAP levels (≥0.04 ng/mL) were found pre-operatively in 52 % of patients and post-operatively in 96 %. Detectable pGFAP was more common in patients with WHO grade IV (100 %) than WHO grade III (56 %) or WHO grade II gliomas (20 %). No patient with undetectable GFAP had WHO grade IV glioma. Higher pGFAP concentrations were also associated with contrast enhancement but not related to tumor GFAP expression. GFAP is commonly detected in the plasma of patients with high-grade gliomas. pGFAP levels rise rather than fall following debulking surgery which is probably a result of surgical trauma. GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes.

KW - Biomarker

KW - Circulating tumor marker

KW - Glial fibrillary acidic protein

KW - Glioblastoma

KW - Glioma

UR - http://www.scopus.com/inward/record.url?scp=84864285431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864285431&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0874-8

DO - 10.1007/s11060-012-0874-8

M3 - Article

C2 - 22492246

AN - SCOPUS:84864285431

VL - 109

SP - 123

EP - 127

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -